Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Orix to Acquire Majority Stake in Generic Drug Maker Kobayashi Kako
January 16, 2020
- ASKA Bags Japan Rights for Cervical Dysplasia Therapy from Kyoto Univ. Spinoff
January 16, 2020
- Tapped as Next Mitsubishi Tanabe Chief, Hiroaki Ueno Vows to Enrich Pipeline, Accelerate Global Biz
January 15, 2020
- Astellas, Adaptimmune Hook Up on Off-the-Shelf Cell Therapies
January 15, 2020
- Crysvita Filed for Add’l Indication Tumor-Induced Osteomalacia in US
January 15, 2020
- Japan Ethical Drug Sales Slip 1.1% in November 2019: Crecon
January 14, 2020
- Hisamitsu to Establish Subsidiary in Malaysia in October
January 14, 2020
- Eisai Cancer Drug Halaven Goes on Sale in China
January 14, 2020
- Kaken Files Axillary Hyperhidrosis Med in Japan
January 14, 2020
- Healios to Develop Next-Generation Cancer Immunotherapy
January 14, 2020
- Sumitomo Dainippon’s Altavant Picks Up Onspira
January 10, 2020
- Chugai Licenses KRAS-Targeting Drug to Verastem
January 10, 2020
- Keytruda Remains Top-Seller in December Drug Ranking in Japan: Encise
January 10, 2020
- Hisamitsu Starts 2 PIII Studies for NSAIDs Patch, Plans Filing by February 2022
January 10, 2020
- Bristol-Myers Japan Chief Doubles as Celgene President amid Transition
January 10, 2020
- US District Court Dismisses Asahi Kasei’s Request for Continuing Supply of Xiaflex
January 10, 2020
- Meiji Gains Japan Rights for Novel Blood Cancer Treatment from HUYA Bioscience
January 10, 2020
- Keytruda Top New Sales Generator in 2020, Enhertu Seen as Biggest Arrival: Evaluate
January 9, 2020
- Kyowa Kirin Seeks Add’l Indication for Lumicef
January 9, 2020
- Mitsubishi Chemical to Purchase 197 Million Shares of Mitsubishi Tanabe, Taking Over 90% Ownership
January 9, 2020
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…